CX3CL1 and neurodegenerative disease: Although more work needs to be done to determine the therapeutic viability of FKN overexpression, these studies suggest that the use of targeted viral vectors, therapeutic peptides, or potentially pharmacological CX3CR1 receptor agonists, to target the FKN signaling axis could prove to be a viable treatment option for a variety of neurodegenerative diseases.